ANI Pharmaceuticals, Inc. (ANIP:NASDAQ) closed at $71.44 on November 13, 2026, up 0.53% on the day. The stock trades 18.6% below its 52-week high of $87.76 and 6.4% above its 52-week low of $67.14. Over the past year, it lost 15.0%. ANI Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, ANIP closed higher on 125 days (50%). Its best day was January 12, 2026 (+10.58%) and its worst was January 9, 2026 (-5.87%). The stock moved 10% or more in a single session 1 time.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to trea...
Find more stocks like ANIP with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.